PTC Therapeutics Logo
US69366J2006
A1W0MW
PTCT

PTC Therapeutics

Forecast

The analysts' average price target is €93.77 (+82.29%). The median is €94.78 (+84.25%).

Buy
  18
Hold
  6
Sell
  2

Discussions in the community

There is no discussion about this asset yet.

Start discussion

Historical dividends Dividends

All dividend metrics All metrics

In 2013, PTC Therapeutics has already paid €0.0663 in dividends. The last payout was in June 2013.

Financials

In the last quarter, PTC Therapeutics had revenue of €315.89M and net profit of -€45.64M

(EUR) September 2026
YoY
Revenue 315.89M 75.68%
Gross profit 295M 264.15%
Net profit -45.64M 436.92%
EBITDA 19.07M 8.47%

Fundamentals

Metric Value
Market capitalization
€4.3B
Number of shares
83.54M
52-week high/low
€82.81 - €51.20
Dividends No
Beta
0.51
P/E ratio
-43.07
PEG ratio
0.61
P/B ratio
-24.63
P/S ratio
4.08

Company profile

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Name
PTC Therapeutics
CEO
Matthew Klein
Headquarters Warren, nj
USA
Website
Sector
Materials
Industry
Chemicals
IPO
06/20/2013
Employees 991

Ticker symbols

Exchange Symbol
NASDAQ
PTCT
Frankfurt
BH3.F
DĂĽsseldorf
BH3.DU
SIX
P91.SW
MĂĽnchen
BH3.MU
🍪

Parqet  uses cookies. Learn more